导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.13% | 4166/4773 |
| 近一周 | -2.38% | 3794/5465 |
| 近一月 | -0.08% | 722/5421 |
| 近一季 | -9.16% | 3508/5231 |
| 近半年 | -18.67% | 4309/4920 |
| 近一年 | -2.87% | 3080/4394 |
| 近两年 | 43.10% | 1763/2954 |
| 近三年 | 12.00% | 1705/2253 |
| 成立以来 | 41.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.05% 3752/4961 |
-1.77% 3363/5312 |
- - |
- - |
| 2025 | 31.67% 1222/4813 |
-1.85% 2798/3635 |
11.93% 122/4076 |
7.67% 3441/4524 |
11.31% 171/4813 |
| 2024 | 8.36% 1561/3463 |
-6.27% 2036/2808 |
-2.40% 1185/3014 |
13.27% 2200/3129 |
4.58% 692/3463 |
| 2023 | -10.56% 1314/2656 |
1.42% 1573/2280 |
3.20% 102/2385 |
-10.76% 2021/2515 |
-4.24% 929/2655 |
| 2022 | -26.36% 1393/2207 |
-22.82% 1717/1919 |
3.69% 1107/2016 |
-7.28% 122/2113 |
-0.77% 1645/2208 |
| 2021 | 13.75% 351/1822 |
-18.77% 1206/1255 |
10.53% 456/1330 |
7.57% 178/1466 |
17.77% 41/1822 |
| 2020 | 69.38% 74/1250 |
-1.17% 206/1028 |
11.42% 733/1067 |
30.29% 11/1164 |
18.06% 105/1184 |
| 2019 | 23.15% 634/1092 |
32.75% 166/754 |
-9.71% 682/804 |
4.05% 222/850 |
-1.26% 899/918 |
| 2018 | -26.98% 409/834 |
- - |
- - |
- - |
-13.79% 556/691 |
| 2017 | -13.90% 557/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 国泰中证军工ETF VS. 长安沪深300非周期A(740101) |